Padlan E A
Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
Mol Immunol. 1991 Apr-May;28(4-5):489-98. doi: 10.1016/0161-5890(91)90163-e.
It is proposed to reduce the immunogenicity of allogeneic antibody variable domains, while preserving ligand-binding properties, by reducing their antigenicity through replacement of the exposed residues in the framework regions which differ from those usually found in host antibodies. The results of a comparison of representative murine antibody sequences with those of human origin suggest that the number of residues that need to be replaced to "humanize" those antibodies could be small.
有人提议,通过替换框架区中与宿主抗体中通常发现的残基不同的暴露残基来降低其抗原性,从而在保留配体结合特性的同时降低同种异体抗体可变区的免疫原性。将代表性鼠源抗体序列与人类来源的抗体序列进行比较的结果表明,使这些抗体“人源化”所需替换的残基数量可能很少。